MediGene AG · LS:A40ESG
MediGene — Q1 2010 Earnings Presentation
12 slides from MediGene's earnings presentation, Mar 26, 2010
Slide 1: Earnings call Q1/2010
Earnings call March 26, 2010 Q1/2010 Dr. Frank Mathias, CEO Arnd Christ, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intents", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Overview
Overview Dr. Frank Mathias, CEO
Slide 4: Successful start in year 2010
Successful start in year 2010 Products • Veregen®: - launched in Germany by Solvay - extension of marketing activities in the US - Marketing partnerships for Veregen® closed with Teva for Israel and Meditrina for Greece and Cyprus • Eligard® : - Increased revenues in first three months Pipeline
Slide 5: EndoTAG-1: Phase II trial preliminary results published yesterday
EndoTAG™-1: Phase II trial preliminary results published yesterday First, preliminary results obtained in a phase II trial of EndoTAG™-1 for the treatment of triple receptor-negative breast cancer Primary endpoint (16 weeks PFS rate of at least 30%) was • Met by EndoTAG™-1 in combination therapy
Slide 6: Financials
Financials Arnd Christ, CFO
Slide 7: Earnings Q1 2010
Earnings Q1 2010 Total revenue Cost of sales Gross profit in € million, rounded in € million, rounded in € million, rounded 12.0 11.6 12% Product - 12% sales & royalties + 11% Q1 2010 Q1 2009 Q1 2010 Q1 2009 Q1 2010 Q1 2009 Product sales & royalties Other revenue and milestone payments Increase of
Slide 8: Operating expenses, EBITDA, net loss Q1 2010
Operating expenses, EBITDA, net loss Q1 2010 Operating expenses EBITDA loss Net loss in € million, rounded in € million, rounded in € million, rounded 21% 31% 5.9 5.9 2.4 2.3 1.9 1.9 Q1 2010 Q1 2009 Q1 2010 Q1 2009 Q1 2010 Q1 2009 Expenses remain mainly stable Increase of EBITDA loss by 31% to €
Slide 9: Cash flow analysis
Cash flow analysis Development of cash Monthly cash burn in € million, rounded in € million, rounded 6,0 - 29 % 12.3 6.0 0.1 2.0 2.8 8.2 2.0 8,2 Dec 31, Operating Investing Financing March 31, Q1 2010 Q1 2009 2009 activities activities activities 2010 Cash reserves as of March 31, 2010: € 8.2 mill
Slide 10: Outlook
Outlook Dr. Frank Mathias, CEO
Slide 11: Outlook 2010
Outlook 2010 EndoTAG™-1: Conclusion of partnering deal anticipated Eligard®: Increasing revenues expected Veregen®: Increasing revenues expected and additional marketing partnerships to be concluded RhuDex®: Evaluation of preclinical trial results as basis for resumption of clinical developm
Slide 12: MediGene AG contact details
MediGene AG MediGene Ltd. MediGene Inc. Lochhamer Straße 11 57c Milton Park 10650 Scripps Ranch Blvd., 82152 Planegg / Martinsried, Abingdon, Oxon, OX14 4RX Suite 230 Germany United Kingdom San Diego, CA 92131, USA Phone: +49 89 85 65 29 00 Phone: +44 1235 438600 Phone: (858) 586 2240 Fax: +49 89 85